ALTERATION OF THIOREDOXIN REDUCTASE 1 LEVELS IN ELUCIDATING CANCER ETIOLOGY

被引：11

作者：

Yoo, Min-Hyuk ^{[1
]}

Carlson, Bradley A. ^{[1
]}

Tsuji, Petra ^{[1
,2
,5
]}

Irons, Robert ^{[1
]}

Gladyshev, Vadim N. ^{[3
,4
]}

Hatfield, Dolph L. ^{[1
]}

机构：

[1] NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA

[2] NCI, Nutr Sci Res Grp, Canc Prevent Div, NIH, Bethesda, MD 20892 USA

[3] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Boston, MA USA

[5] NCI, Canc Prevent Fellowship Program, NIH, Bethesda, MD 20892 USA

来源：

METHODS IN ENZYMOLOGY, VOL 474: THIOL REDOX TRANSITIONS IN CELL SIGNALING, PT B: CELLULAR LOCALIZATION AND SIGNALING | 2010年 / 474卷

关键词：

SELENIUM; SELENOCYSTEINE; SELENOPROTEINS; CELLS; THIOREDOXIN-REDUCTASE-1; TRANSCRIPTION; EXPRESSION; PREVENTION; PHENOTYPE; SYSTEM;

D O I：

10.1016/S0076-6879(10)74015-5

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Thioredoxin reductase 1 (TR1) is a major antioxidant and redox regulator in mammalian cells and appears to function as a double-edged sword in that it has roles in preventing and promoting/sustaining cancer. TR1 is overexpressed in many cancer cells and targeting its removal often leads to a reversal in numerous malignant characteristics which has marked this selenoenzyme as a prime target for cancer therapy. Since alterations in TR1 activity may lead to a better understanding of the etiology of cancer and new avenues for providing better therapeutic procedures, we have described herein techniques for removing and reexpressing TR1 employing RNAi technology and for assessing the catalytic activity of this enzyme.

引用

页码：255 / 275

页数：21

共 49 条

[11] Human selenoproteins at a glance
Gromer, S
Eubel, JK
Lee, BL
Jacob, J
[J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2005, 62 (21) : 2414 - 2437
[12] Negation of the cancer-preventive actions of selenium by over-expression of protein kinase Cε and selenoprotein thioredoxin reductase
Gundimeda, Usha
Schiffman, Jason Eric
Gottlieb, Simcha Neeli
Roth, Brandon Ian
Gopalakrishna, Rayudu
[J]. CARCINOGENESIS, 2009, 30 (09) : 1553 - 1561
[13] The hallmarks of cancer
Hanahan, D
Weinberg, RA
[J]. CELL, 2000, 100 (01) : 57 - 70
[14] HATFIELD DL, 2007, CCR FRONTIERS SCI, V6, P8
[15] Selenoproteins that function in cancer prevention and promotion
Hatfield, Dolph L.
Yoo, Min-Hyuk
Carlson, Bradley A.
Gladyshev, Vadim N.
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2009, 1790 (11): : 1541 - 1545
[16] The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) Reveals the Need for Better Understanding of Selenium Biology
Hatfield, Dolph L.
Gladyshev, Vadim N.
[J]. MOLECULAR INTERVENTIONS, 2009, 9 (01) : 18 - 21
[17] p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA
Hedstrom, Elisabeth
Eriksson, Sofi
Zawacka-Pankau, Joanna
Arner, Elias S. J.
Selivanova, Galina
[J]. CELL CYCLE, 2009, 8 (21) : 3584 - 3591
[18] Determination of thioredoxin reductase activity in rat liver supernatant
Hill, KE
McCollum, GW
Burk, RF
[J]. ANALYTICAL BIOCHEMISTRY, 1997, 253 (01) : 123 - 125
[19] Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element
Hintze, KJ
Wald, KA
Zeng, HW
Jeffery, EH
Finley, JW
[J]. JOURNAL OF NUTRITION, 2003, 133 (09) : 2721 - 2727
[20] HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199

← 1 2 3 4 5 →